Cargando…

The Case for Early Use of Glucagon-like Peptide-1 Receptor Agonists in Obstructive Sleep Apnea Patients with Comorbid Diabetes and Metabolic Syndrome

Patients with obstructive sleep apnea (OSA) have high rates of co-occurring type 2 diabetes, hypertension, obesity, stroke, congestive heart failure, and accelerated atherosclerotic cardiovascular diseases. These conditions frequently require multiple medications, raising the risk of polypharmacy, a...

Descripción completa

Detalles Bibliográficos
Autores principales: Sultana, Rizwana, Sissoho, Fatoumatta, Kaushik, Vinod P., Raji, Mukaila A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9410036/
https://www.ncbi.nlm.nih.gov/pubmed/36013401
http://dx.doi.org/10.3390/life12081222
_version_ 1784774996768325632
author Sultana, Rizwana
Sissoho, Fatoumatta
Kaushik, Vinod P.
Raji, Mukaila A.
author_facet Sultana, Rizwana
Sissoho, Fatoumatta
Kaushik, Vinod P.
Raji, Mukaila A.
author_sort Sultana, Rizwana
collection PubMed
description Patients with obstructive sleep apnea (OSA) have high rates of co-occurring type 2 diabetes, hypertension, obesity, stroke, congestive heart failure, and accelerated atherosclerotic cardiovascular diseases. These conditions frequently require multiple medications, raising the risk of polypharmacy, adverse drug–drug and drug–disease interactions, decreased quality of life, and increased healthcare cost in these patients. The current review of extant literature presents evidence supporting glucagon-like peptide-1 receptor agonists (GLP-1RA) as one pharmacologic intervention that provides a “one-stop shop” for OSA patients because of the multiple effects GLP-1RA has on comorbidities (e.g., hypertension, diabetes, obesity, metabolic syndrome, and atherosclerotic cardiovascular diseases) that commonly co-occur with OSA. Examples of glucagon-like peptide-1 receptor agonists approved by the FDA for diabetes (some of which are also approved for obesity) are liraglutide, exenatide, lixisenatide, dulaglutide, semaglutide, and albiglutide. Prescribing of GLP-1RAs to address these multiple co-occurring conditions has enormous potential to reduce polypharmacy, cost, and adverse drug events, and to improve quality of life for patients living with OSA and diabetes. We thus strongly advocate for increased and early use of GLP-1RA in OSA patients with co-occurring diabetes and other cardiometabolic conditions common in OSA.
format Online
Article
Text
id pubmed-9410036
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-94100362022-08-26 The Case for Early Use of Glucagon-like Peptide-1 Receptor Agonists in Obstructive Sleep Apnea Patients with Comorbid Diabetes and Metabolic Syndrome Sultana, Rizwana Sissoho, Fatoumatta Kaushik, Vinod P. Raji, Mukaila A. Life (Basel) Commentary Patients with obstructive sleep apnea (OSA) have high rates of co-occurring type 2 diabetes, hypertension, obesity, stroke, congestive heart failure, and accelerated atherosclerotic cardiovascular diseases. These conditions frequently require multiple medications, raising the risk of polypharmacy, adverse drug–drug and drug–disease interactions, decreased quality of life, and increased healthcare cost in these patients. The current review of extant literature presents evidence supporting glucagon-like peptide-1 receptor agonists (GLP-1RA) as one pharmacologic intervention that provides a “one-stop shop” for OSA patients because of the multiple effects GLP-1RA has on comorbidities (e.g., hypertension, diabetes, obesity, metabolic syndrome, and atherosclerotic cardiovascular diseases) that commonly co-occur with OSA. Examples of glucagon-like peptide-1 receptor agonists approved by the FDA for diabetes (some of which are also approved for obesity) are liraglutide, exenatide, lixisenatide, dulaglutide, semaglutide, and albiglutide. Prescribing of GLP-1RAs to address these multiple co-occurring conditions has enormous potential to reduce polypharmacy, cost, and adverse drug events, and to improve quality of life for patients living with OSA and diabetes. We thus strongly advocate for increased and early use of GLP-1RA in OSA patients with co-occurring diabetes and other cardiometabolic conditions common in OSA. MDPI 2022-08-12 /pmc/articles/PMC9410036/ /pubmed/36013401 http://dx.doi.org/10.3390/life12081222 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Commentary
Sultana, Rizwana
Sissoho, Fatoumatta
Kaushik, Vinod P.
Raji, Mukaila A.
The Case for Early Use of Glucagon-like Peptide-1 Receptor Agonists in Obstructive Sleep Apnea Patients with Comorbid Diabetes and Metabolic Syndrome
title The Case for Early Use of Glucagon-like Peptide-1 Receptor Agonists in Obstructive Sleep Apnea Patients with Comorbid Diabetes and Metabolic Syndrome
title_full The Case for Early Use of Glucagon-like Peptide-1 Receptor Agonists in Obstructive Sleep Apnea Patients with Comorbid Diabetes and Metabolic Syndrome
title_fullStr The Case for Early Use of Glucagon-like Peptide-1 Receptor Agonists in Obstructive Sleep Apnea Patients with Comorbid Diabetes and Metabolic Syndrome
title_full_unstemmed The Case for Early Use of Glucagon-like Peptide-1 Receptor Agonists in Obstructive Sleep Apnea Patients with Comorbid Diabetes and Metabolic Syndrome
title_short The Case for Early Use of Glucagon-like Peptide-1 Receptor Agonists in Obstructive Sleep Apnea Patients with Comorbid Diabetes and Metabolic Syndrome
title_sort case for early use of glucagon-like peptide-1 receptor agonists in obstructive sleep apnea patients with comorbid diabetes and metabolic syndrome
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9410036/
https://www.ncbi.nlm.nih.gov/pubmed/36013401
http://dx.doi.org/10.3390/life12081222
work_keys_str_mv AT sultanarizwana thecaseforearlyuseofglucagonlikepeptide1receptoragonistsinobstructivesleepapneapatientswithcomorbiddiabetesandmetabolicsyndrome
AT sissohofatoumatta thecaseforearlyuseofglucagonlikepeptide1receptoragonistsinobstructivesleepapneapatientswithcomorbiddiabetesandmetabolicsyndrome
AT kaushikvinodp thecaseforearlyuseofglucagonlikepeptide1receptoragonistsinobstructivesleepapneapatientswithcomorbiddiabetesandmetabolicsyndrome
AT rajimukailaa thecaseforearlyuseofglucagonlikepeptide1receptoragonistsinobstructivesleepapneapatientswithcomorbiddiabetesandmetabolicsyndrome
AT sultanarizwana caseforearlyuseofglucagonlikepeptide1receptoragonistsinobstructivesleepapneapatientswithcomorbiddiabetesandmetabolicsyndrome
AT sissohofatoumatta caseforearlyuseofglucagonlikepeptide1receptoragonistsinobstructivesleepapneapatientswithcomorbiddiabetesandmetabolicsyndrome
AT kaushikvinodp caseforearlyuseofglucagonlikepeptide1receptoragonistsinobstructivesleepapneapatientswithcomorbiddiabetesandmetabolicsyndrome
AT rajimukailaa caseforearlyuseofglucagonlikepeptide1receptoragonistsinobstructivesleepapneapatientswithcomorbiddiabetesandmetabolicsyndrome